Loading
A 2008 MD Anderson series showing that 57 percent of breast cancers in BRCA1 carriers were triple-negative against 14 percent in women without a BRCA fault, the clinical number behind the rule that triple-negative diagnosis should prompt a genetic test.
Atchley, Albarracin, Lopez, Valero and colleagues examined tumour pathology and clinical characteristics in 491 women with breast cancer who had genetic testing for BRCA mutations between 1997 and 2006; 391 were BRCA-negative and 86 BRCA-positive. Triple-negative breast cancer was diagnosed in 57.1 percent of BRCA1-positive patients, 23.3 percent of BRCA2-positive patients and 13.8 percent of BRCA-negative patients. BRCA1 carriers had higher nuclear grade tumours (p<0.001), and among triple-negative patients BRCA2 carriers were older at diagnosis than BRCA1 carriers and non-carriers (p<0.01). The authors suggest BRCA1-associated tumours divide into triple-negative and non-triple-negative groups.
Turned the laboratory link between BRCA1 and basal-like biology into a clinical rule: a triple-negative diagnosis is itself a reason to offer germline testing, now embedded in NICE, NCCN and ESMO criteria.
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing and the tag tnbc-evidence.
Shares Inherited risk is mostly unidentified, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares BRCA1 / BRCA2 (HRD), Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares MD Anderson Cancer Center, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares A UK audit of trial access and germline testing uptake in triple-negative breast cancer, Germline (hereditary) testing, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.